Generate Biomedicines, Inc. Restricted Cash and Cash Equivalents, Noncurrent
Generate Biomedicines, Inc. (GENB) had Restricted Cash and Cash Equivalents, Noncurrent of $4.03 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2026-08-06
- 2026-06-30: Restricted Cash and Cash Equivalents, Noncurrent $4.03M.
- 2026-03-31: Restricted Cash and Cash Equivalents, Noncurrent $4.03M.
- 2025-06-30: Restricted Cash and Cash Equivalents, Noncurrent $4.04M.
- 2025-03-31: Restricted Cash and Cash Equivalents, Noncurrent $4.04M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2026-06-30 | $4.03M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.03M 10-Q · filed 2026-05-07 |
| 2025-06-30 | $4.04M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $4.04M 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |